

Deriving a Novel Index for Objective Probabilistic Prediction of Parkinson's



Dauche, Alex^{1,5}; Kovalev, Vicky^{2,5}; Menon, Aditya^{3,5}; Yenamandra, Siddharth^{4,5}

Interlake High School, Bellevue, WA, 98008-2492¹; Sherman Oaks Center for Enriched Studies, Tarzana, CA, 91335²; Fulton Science Academy Private School, Alpharetta, GA, 30009³; Eastlake High School, Sammamish, WA, 98074-7209⁴; Boston University, Boston, MA 022156

Introduction

- **Parkinson's Disease (PD)** is a progressive neurodegenerative disease characterized by tremors, dementia, and mood swings
- The **Unified Parkinson's Rating Scale (UPDRS)** is an index that assesses PD severity
- UPDRS is based on 16 subjective factors; due to this, it performs poorly at predicting PD likelihood
- In hopes of improving on current standard prediction indexes, we created STRIPE and PRISM
- **STRIPE (Statistical Tool for Risk Indexing and Parkinson's Evaluation)** is an objective index that uses only 14 variables for predicting PD onset. It can be combined with UPDRS to further improve prediction accuracy
- **PRISM (Parkinson's Risk Index via Survey Measurements)** is a simplified index that uses 12 objective binary factors designed for remote, baseline assessments

Methods

- **STRIPE:** Weighted via logistic regression optimization to maximize correlation with PD diagnosis
- **PRISM:** Subset of features from STRIPE (age, tremors, diabetes) with weights calculated similarly
- **Model-Based Evaluation:** Testing accuracy & correlation of indexes' feature coefficients using logistic regression, random forest, and gradient boosting classifiers
 - Classifiers determine indexes' accuracy for model-based usage, uses ROC AUC to check for overfitting
 - Pearson correlation assesses model performance for human usage




Figure 1: Methodology Pipeline for PD Diagnosis

Results




Figure 2: ROC (Receiver Operating Curve) Curve Showing Diagnostic Performance of UPDRS, STRIPE, & PRISM




Figure 3: UPDRS, STRIPE, & PRISM index distribution across participants in highest-performing classifier




Figure 4: Key features influencing STRIPE & PRISM indices

Index Equations

STRIPE: $\text{Sigmoid}(0.498\text{Pi} + 0.770\text{T} - 0.674\text{Fa} - 0.439\text{MoCA} + 0.569\text{Bk} + 0.595\text{R} + 0.196\text{A} + 0.109\text{D} + 0.015\text{FhP} + 0.114\text{Di} + 0.091\text{S} - 0.001\text{Sp} - 0.089\text{Sd} + 0.3\text{FaT} + 0.2\text{FaR} + 0.2\text{FaBk} + 0.2\text{FaPi} - 0.200\text{TBk} - 0.400\text{TPi} - 0.2\text{RBk} - 0.1\text{AFa} + 0.712)$

PRISM: $\text{Sigmoid}(0.436\text{Pi} + 0.690\text{T} + 0.515\text{Bk} + 0.519\text{R} + 0.161\text{A} + 0.089\text{D} + 0.029\text{Fhp} + 0.089\text{D} + 0.141\text{Di} + 0.062\text{S} - 0.013\text{Sp} - 0.052\text{Sd} - 0.2\text{TBk} - 0.4\text{TPi} - 0.2\text{RBk} + 0.638)$

Discussion

Significance: STRIPE and PRISM provide objective indexes that improve upon traditional PD diagnosis

- **Higher diagnostic accuracy:**
 - STRIPE and PRISM outperform UPDRS in both ROC AUC and correlation with diagnosis (0.553 vs 0.443 vs 0.398) (Figure 2)
 - STRIPE when combined with UPDRS yields performance accuracy of 87.7%: a significant improvement over individual model evaluations
- **Two indexes:** Despite lower accuracy (70% vs. 77%), the accessibility of the PRISM assessment makes it a worthy alternative to UPDRS. STRIPE acts as a secondary predictive measure, meeting UPDRS' accuracy

Limitations:

- Lacks external clinical or biomarker validation
- Dataset is very limited and could lead to coefficient overfitting

Future Applications:

- Validate STRIPE and PRISM using longitudinal clinical data
- Using STRIPE as a support tool for clinicians

References

- Gill, D. J., Freshman, A., Blender, J. A., & Ravina, B. (2008). The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. *Movement disorders: official journal of the Movement Disorder Society*, 23(7), 1043-1046.
- Hendricks, Renee M, and Mohammad T Khasawneh. "An Investigation into the Use and Meaning of Parkinson's Disease Clinical Scale Scores." *Parkinson's disease* vol. 2021 1765220. 29 May. 2021, doi:10.1155/2021/1765220
- Evers, Luc J.W., et al. "Measuring parkinson's disease over time: The Real-world within-Subject Reliability of the MDS-UPDRS." *Movement Disorders*, vol. 34, no. 10, 10 July 2019, pp. 1480-1487, https://doi.org/10.1002/mds.27790.
- Kharoua, Rabie El. "Parkinson's Disease Dataset Analysis." *Kaggle*, 2024. https://doi.org/10.34740/KAGGLE/DSV/8668551.

Acknowledgements

We sincerely thank Karla Montejo, Shankar Ramachandran, and the entire team of teaching fellows for their invaluable guidance throughout this project. We are also grateful to the Boston University Summer Term Program for providing this incredible research opportunity. Lastly, we would like to thank our families for their never-ending support